Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

77.31EUR
5:12am EDT
Price Change (% chg)

€0.18 (+0.23%)
Prev Close
€77.13
Open
€77.17
Day's High
€77.47
Day's Low
€77.10
Volume
358,207
Avg. Vol
2,884,595
52-wk High
€87.03
52-wk Low
€68.29

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.59
Market Cap (Mil.): €102,239.90
Shares Outstanding (Mil.): 1,325.60
Dividend: 2.80
Yield (%): 3.63

Financials

  SASY.PA Industry Sector
P/E (TTM): 27.85 32.71 32.86
EPS (TTM): 2.77 -- --
ROI: 4.56 19.60 18.86
ROE: 6.51 20.30 19.62
Search Stocks

Sanofi to resubmit Lemtrada application for FDA review

PARIS, April 7 - Sanofi said it plans to resubmit its application for its Lemtrada drug for the treatment of relapsing forms of multiple sclerosis following "constructive discussions" with the U.S. Food and Drug Administration.

07 Apr 2014

Sanofi eyes more acquisitions, sees growth in Africa

PARIS - Sanofi is on the lookout for acquisitions to boost key business units, such as consumer and animal health products, and expects strong growth in the "strategic continent" of Africa, its chief executive told Reuters on Wednesday.

02 Apr 2014

Sanofi faces make-or-break verdict on big dengue vaccine bet

NEUVILLE-SUR-SAONE, France - Sanofi expects final clinical results for its vaccine against dengue by late September, the French drugmaker's project leader has told Reuters, and has already gambled on starting production despite some disappointing early trials data.

25 Mar 2014

Sanofi faces make-or-break verdict on big dengue vaccine bet

* Sales could top 1 bln euros but project is risky -analysts

25 Mar 2014

Sanofi teams up with South Korean group on pneumococcal vaccine

PARIS - French drugmaker Sanofi said its Sanofi Pasteur unit had signed a long-term cooperation deal with South Korea's SK Chemical Co to develop and market a vaccine against pneumococcal infection.

19 Mar 2014

Sanofi teams up with South Korean group on pneumococcal vaccine

PARIS, March 19 - French drugmaker Sanofi said its Sanofi Pasteur unit had signed a long-term cooperation deal with South Korea's SK Chemical Co to develop and market a vaccine against pneumococcal infection.

19 Mar 2014

Rivals race to develop new biotech asthma drugs

* GSK leads new wave with mepolizumab due for 2014 filing

18 Mar 2014

Sanofi, UCB set up drug development partnership

PARIS - French and Belgian drugmakers Sanofi and UCB have entered a partnership aimed at finding treatments for so-called immune-mediated diseases in areas such as rheumatoid arthritis and inflammatory bowel conditions.

11 Mar 2014

Sanofi, UCB set up drug development partnership

PARIS, March 11 - French and Belgian drugmakers Sanofi and UCB have entered a partnership aimed at finding treatments for so-called immune-mediated diseases in areas such as rheumatoid arthritis and inflammatory bowel conditions.

11 Mar 2014

FDA probes cognitive impact of new cholesterol drugs

- The Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday.

07 Mar 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Pechala's Reports
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks